Suresnes (France), January 8, 2026 – Servier, an independent international pharmaceutical company governed by a Foundation, announces the creation of Servier Ventures, a fully owned corporate venture fund. The fund is committed to investing an initial amount of €200 million in innovative biotech and technological companies.
The primary goal is to invest in biotech companies shaping the future of oncology and neurology, expanding Servier’s reach across the global innovation ecosystem to advance science and unlock tomorrow’s breakthrough therapies for the benefit of patients.
Building on Servier’s existing innovation efforts and its investments as a limited partner in venture capital, Servier Ventures will further reinforce the Group’s position within the innovation ecosystem.
“The creation of Servier Ventures is fully aligned with our mission to drive therapeutic progress and address unmet patient needs. Today, we invest a significant portion of our sales to develop our R&D pipeline. This commitment includes supporting innovative companies seeking to deliver transformative scientific solutions for patients.”
Olivier Laureau, President of Servier
Investments will be made through minority stakes in innovative biotech and technological companies operating within Servier’s therapeutic fields of oncology and neurology. Initially, this fund will primarily invest in Europe with the possibility of expanding to other regions in the future.
“In line with the Group’s strategy, Servier Ventures will finance and support emerging biotech companies and, if needed, provide them access to Servier’s scientific expertise and capabilities, to boost their potential and foster the creation of innovative new medicines. The creation of the fund will strengthen Servier’s positioning as a partner of choice for promising companies seeking to take a strategic step forward, aligned with our focus toward innovation for the benefit of patients.”
Alexis Vandier, newly appointed Global Head of Servier Ventures